直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Spotlight on Upcoming Oral Arguments – May 2017

May 01, 2017

Authored and Edited by Caitlin E. Fowler; Lillian M. Robinson; Elizabeth D. Ferrill

Monday, May 1, 2017

Intervet v. E.I. DuPont de Nemours, No. 16-2131, Courtroom 402

In this appeal, the Federal Circuit has been asked to determine whether the AIA eliminated district court review of post-AIA interference decisions, and if so, whether the Court should review interference decisions de novo.  Intervet argues that the Court should overrule its Biogen v. Japanese Found. for Cancer Research decision and find that district court review is still available.  Alternatively, Intervet argues that the Court should overrule its Merck & Cie v. Gnosis decision and find that the Federal Circuit should review the Board’s determination of priority de novo.  DuPont argues that the Court’s decisions in Biogen and Gnosis were correctly decided, should not be disturbed, and cannot be revisited absent en banc review.

Wednesday, May 3, 2017

GoDaddy.com v. Rpost Communications, No. 16-2335, Courtroom 402

This appeal arises from a D. Ariz. decision in which Rpost’s patents were held invalid under § 101.  Rpost argues that the district court did not have jurisdiction to hear GoDaddy’s § 101 challenge because patent ineligibility is not an enumerated litigation defense under § 282(b).  GoDaddy argues that the Federal Circuit has long recognized that § 282 defenses include the “conditions of patentability” in § 101.  This issue will be addressed in light of the Court’s holding in Versata v. SAP Am., in which the Court determined that the PTAB has the authority to consider § 101 challenges.

Shinn Fu Co. of America v. Tire Hanger Corp, No. 16-2250, Courtroom 203

Shinn Fu appeals the PTAB’s grant of Tire Hanger’s motion to amend its claims.  Shinn Fu argues that Tire Hanger failed to carry its burden to prove the patentability of its substitute claims because it did not address every possible combination of the prior art of record.  Tire Hanger argues that the Board does not have to address every possible combination of the prior art of record when considering a motion to amend.

Google v. Intellectual Ventures II, No. 16-1543, Courtroom 201

Google appeals from a PTAB decision finding the ’690 patent was not invalid as anticipated.  Google argues that the Board erred in finding that the prior art did not disclose “logical operators,” which it characterizes as “basic, well-known elements of computer science.”  Intellectual Ventures argues that Google failed to carry its burden of establishing unpatentability as its petition did not show that the prior art expressly or inherently disclosed “logical operators.”

Thursday, May 4, 2017

Wi-Fi One v. Broadcom, No. 15-1944, Courtroom 201

In this en banc appeal, the Federal Circuit will address whether § 314(d) precludes review of the Board’s determination that the Petitioner satisfied the timeliness requirement for filing an IPR petition.  Broadcom argues that under the Court’s decision in Achates, there is no exception under § 314(d) for review of the Board’s timeliness determination.  Wi-Fi One argues that Achates should not be construed so strictly and that § 314(d) only precludes interlocutory appeal of the Board’s institution, not the reviewability of the Board’s compliance with the time-bar of § 315(b) on appeal of a final written decision.

 

Tags

Spotlight on Upcoming Oral Arguments

Contacts

Elizabeth D. Ferrill
Partner
Washington, DC
+1 202 408 4445
Email

Copyright © 2017 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

INCONTESTABLE® Blog

Netflix Prevails in Copyright Infringement Suit Regarding Tiger King

May 14, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP